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Snakebite is a neglected tropical disease that causes high global rates of mortality and mor-
bidity. Although snakebite can cause a variety of pathologies in victims, haemotoxic effects
are particularly common and are typically characterised by haemorrhage and/or venom-
induced consumption coagulopathy. Antivenoms are the mainstay therapeutic for treating
the toxic effects of snakebite, but despite saving thousands of lives annually, these thera-
pies are associated with limited cross-snake species efficacy due to venom variation, which
ultimately restricts their therapeutic utility to particular geographical regions.
Methodology/Principal findings
In this study we explored the feasibility of generating globally effective pathology-specific
antivenoms to counteract the haemotoxic signs of snakebite envenoming. Two different
immunogen mixtures, consisting of seven and twelve haemotoxic venoms sourced from
geographically diverse and/or medically important snakes, were used to raise ovine poly-
clonal antibodies, prior to characterisation of their immunological binding characteristics and
in vitro neutralisation profiles against each of the venoms. Despite variability of the immuno-
gen mixtures, both experimental antivenoms exhibited broadly comparable in vitro venom
binding and neutralisation profiles against the individual venom immunogens in immunologi-
cal and functional assays. However, in vivo assessments using a murine preclinical model
of antivenom efficacy revealed substantial differences in venom neutralisation. The experi-
mental antivenom generated from the seven venom immunogen mixture outperformed the
comparator, by providing protective effects against venom lethality caused by seven of the
eight geographically diverse venoms tested, including three distinct venoms that were not
used as immunogens to generate this antivenom. These findings suggest that a core set of
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venom immunogens may be sufficient to stimulate antibodies capable of broadly neutralis-
ing a geographically diverse array of haemotoxic snake venoms, and that adding additional
venom immunogens may impact negatively on the dose efficacy of the resulting antivenom.
Conclusions/Significance
Although selection of appropriate immunogens that encapsulate venom toxin diversity with-
out diluting antivenom potency remains challenging and further optimisation is required, the
findings from this pilot study suggest that the generation of pathology-specific antivenoms
with global utility is likely to feasible, thereby highlighting their promise as future modular
treatments for the world’s tropical snakebite victims.
Author summary
Snakebite is a major public health concern that causes extensive death and disability in the
tropical world. Variation in venom composition causes major challenges for snakebite
therapy by typically restricting antivenom efficacy to only the few snake species that each
product was designed against, meaning that many geographically restricted therapeutics
are manufactured for different parts of the world. In this study, we explored the feasibility
of generating a global pathology-specific antivenom by using two different sets of haemo-
toxic venoms as immunogens, one including seven venoms and the other twelve venoms,
to generate ovine polyclonal antibodies. Our in vitro immunological cross-reactivity and
venom functional-neutralisation findings demonstrated broadly comparable venom rec-
ognition and inhibition against the various venom immunogens, irrespective of whether
they were included in the immunising mixture. However, assessments of murine in vivo
protection against venom-induced lethality revealed that the antivenom generated with
fewer immunogens outperformed the comparator, and provided broader preclinical effi-
cacy, even against some venoms not used to raise the antibodies. These findings suggest
that careful selection of venoms used as immunogens is crucial for maintaining anti-
venom potency, and that a small subset of venoms may be capable of generating an anti-
venom with potential global efficacy against a specific pathology commonly observed after
snakebite.
Introduction
Snakebite envenoming is classified as a neglected tropical disease (NTD), and as such is most
prevalent in tropical and subtropical regions of the world, particularly rural regions [1,2]. Of
the estimated 5.4 million snakebites thought to occur annually, 1.8–2.7 million of these cases
likely result in envenoming, with as many as 138,000 victims dying as the result of the snake-
bite [2,3].
Snakebites can result in myriad pathophysiological consequences in envenomed victims as
a result of the composition of the aetiological toxins varying extensively among snake species
[4,5]. Despite this variation, most venoms can be broadly classified as inflicting cytotoxic, neu-
rotoxic and/or haemotoxic pathology. Envenoming by viperid snakes (true vipers, Viperinae
and pit vipers, Crotalinae) primarily result in haemotoxic pathologies, typically characterised
by local or systemic haemorrhage, including overt and internal bleeding [6]. Haemorrhage is
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frequently compounded by venom toxin-induced impairment of blood coagulation, which can
result in venom-induced consumption coagulopathy (VICC), defined by untraceable or mini-
mal fibrinogen levels following envenoming [7,8]. While vipers are predominately responsible
for causing life-threatening systemic haemorrhage and VICC in the majority of snakebite
cases, some African colubrids (e.g. Dispholidus typus), Asian natricines (e.g. Rhabdophis sub-
miniatus) and Australasian elapids (e.g. Oxyuranus scutellatus) can also induce VICC as the
result of potent procoagulant toxins in their venoms [7].
The venom toxins primarily thought to be responsible for causing VICC are members of
the snake venom serine protease (SVSP) and snake venom metalloproteinase (SVMP) families
[9,10]. Each of these toxin families is diverse, with multiple related isoforms produced in the
venom gland of each snake species, and these often exhibit distinct functional activities [5,6].
Haemostatic targets for these toxins include Factor X and prothrombin, and their activation
via cleavage stimulates initial procoagulant effects, followed by their consumption and that of
downstream clotting factors, resulting in a loss of clotting capability [11,12]. Other toxins act
directly on fibrinogen in a fibrinogenolytic manner [7], ultimately resulting in its depletion by
this intensified dysregulated activation of the coagulation cascade [13]. In addition, many
viperid venoms also simultaneously contain anticoagulant toxins, such as C-type lectins
(CTLs), phospholipases A2 (PLA2s) and disintegrins, which act by various mechanisms, but
also share a common mode of action by either inhibiting or promoting the aggregation (to
depletion) of platelets [6]. This combination of both procoagulant and anticoagulant toxins in
snake venom [14] can rapidly lead to a loss of clotting capability in an envenomed victim
[7,15,16], and the severity of envenoming can be further compounded by SVMP toxins simul-
taneously disrupting the integrity of the microvasculature via cleavage of extracellular matrix
proteins, resulting in widespread haemorrhage [17,18].
The only specific therapy for snakebite consists of animal-derived polyclonal antibodies,
known as antivenom. Antivenom antibodies exhibit high specificity for venom toxins,
enabling binding, blocking and signalling of toxins for clearance. The production of anti-
venom involves the repeated immunisation of equines or ovines with sub-toxic doses of crude
venom(s), followed by the isolation of the resulting polyclonal immunoglobulin G (IgG) anti-
bodies from the hyper-immune serum/plasma [19,20]. Although a number of antivenom man-
ufacturers digest the IgG antibodies into F(ab’)2 or Fab fragments, others retain the intact IgG
via caprylic acid precipitation [21]. This latter approach has been the basis of conventional IgG
purification since the end of the 1980s [22] and involves the elimination of non-IgG proteins
from the hyperimmune serum/plasma, leaving the IgG intact and thus enhancing antibody
yield via a reduction in process losses [20,23].
Antivenoms are life-saving therapeutics, but they are also associated with a number of limi-
tations. For instance, it has been demonstrated that only 10–20% of antivenom antibodies are
typically specific to the venom immunogens [24], with the remainder thought to target envi-
ronmental antigens animals are exposed to during immunisation [25,26], resulting in poor
dose efficacy. Furthermore, due to their foreign (i.e. animal-derived) active components and
requirement for intravenous (iv) delivery, antivenoms are associated with a high incidence of
acute and chronic adverse reactions, ranging from mild (e.g. rashes) to severe (e.g. anaphy-
laxis) [27–31]. Antivenoms are also prohibitively expensive to the people in greatest need as
treatment courses frequently necessitate the administration of multiple vials (ranging from
3–30 vials depending on product and region), resulting in costs to the patient often exceeding
$1,000 USD in sub-Saharan Africa, for example, and therefore further exacerbate poverty [32].
Finally, and crucially, antivenoms typically exhibit limited cross-snake species efficacy, as the
direct result of variation in venom composition among medically important snake species
[5,33].
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To attempt to mitigate against venom variation many antivenoms currently manufactured
are denotated as polyvalent, where multiple different snake venoms are simultaneously used as
immunogens for generating antibodies. Contrastingly, monovalent antivenoms are made
using a single venom as an immunogen, and are typically manufactured for regions where a
single medically important snake species is responsible for the majority of bites (e.g. Echis ocel-
latus in West Africa) or where a diagnostic test enables rational antivenom choice (currently
only in Australia) [34]. Consequently, for many regions of the world, polyvalent antivenoms
are the most commonly encountered therapeutic due to their capability to cross-react with
and neutralise venoms from various medically important snakes found in a particular region,
thus obviating the requirement for accurate diagnosis of the biting species [34,35]. Despite
their paraspecificity, these products remain restricted for use in certain geographical regions
(i.e. continental or sub-continental), meaning that many different polyvalent antivenom prod-
ucts are manufactured worldwide. However, polyvalent antivenoms are typically associated
with a requirement to deliver higher therapeutic doses than monovalent products due to only
a low proportion of their toxin specific IgGs being specific to the single venom injected during
a snakebite [36], thus increasing both the potential risk of adverse reactions and the financial
cost to the patient.
One of the major challenges associated with manufacturing a polyvalent antivenom for a
specific geographical region is the great diversity of venom toxins found within the venoms of
sympatric viperid and elapid snakes. For example, haemotoxic viper venoms are typically
dominated by SVMP, SVSP, PLA2 and CTL toxin families, while elapid snake venoms, which
are often neurotoxic, typically consist mostly of three finger toxins (3FTx), PLA2 (distinct
from viper PLA2) and/or kunitz-type serine protease inhibitors [37]. Thus, attempting to gen-
erate neutralising antibodies against all of these diverse toxin families simultaneously presents
a major challenge, and there are concerns that the larger, more immunogenic, venom toxins
(e.g. SVMPs, SVSP) may dominate the immune response during immunisation, resulting in
poor recognition of lower molecular weight elapid neurotoxins (e.g. 3FTx), and reduced anti-
venom efficacy against elapid envenoming [38]. In response to this concern, certain antivenom
manufacturers (e.g. Thai Red Cross) now produce polyvalent antivenoms that are separately
specific to haemotoxic vipers and neurotoxic elapids [39,40]. However, each of these antiven-
oms remains geographically restricted for use only in parts of South Asia. More recently,
attempts to produce experimental neurotoxicity-specific antivenoms with broader geographi-
cal efficacy have been described, resulting in a diverse range of venoms being neutralised by
antivenoms raised by immunisation with a diversity of venoms and specific venom toxin frac-
tions [41,42]. A similar pathology-specific approach for counteracting haemotoxic envenom-
ing has also been proposed as a potentially feasible strategy [11].
Consequently, in this study, we explored the feasibility of generating globally applicable,
pathology-specific, polyvalent antivenoms for combatting snakebite haemotoxicity. To do so,
we generated ovine polyclonal antibodies against two groups of venom immunogens, which
contained seven potently coagulopathic venoms and twelve broadly haemotoxic venoms,
respectively, both containing venoms sourced from a wide geographical distribution. We then
assessed the specificity and inhibitory capability of the two resulting experimental IgG-based
antivenoms using a range of in vitro immunological and venom neutralisation assays, before
testing their preclinical efficacy in an in vivomodel of envenoming. Despite differences in the
number of venom immunogens utilised, our findings demonstrate that the inclusion of addi-
tional venom immunogens had a detrimental effect on antivenom efficacy in vivo, though they
also suggest that the generation of generic, globally efficacious pathology-specific, antivenoms
against haemotoxic envenoming is likely to be feasible, though further work focused on the
identification of key venom/toxin immunogens is required to achieve this goal.
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Materials and methods
Ethics statement
All animal experiments were conducted using protocols approved by the Animal Welfare and
Ethical Review Boards of the Liverpool School of Tropical Medicine and the University of Liv-
erpool. They were performed in specific pathogen-free conditions under licensed approval
(PPL #4003718 and #P5846F90) of the UK Home Office and in accordance with the Animal
(Scientific Procedures) Act 1986 and institutional guidance on animal care, which incorporate
humane end point refinements to reduce the extent and duration of pain, harm and distress of
the lowest possible number of experimental mice.
Antivenom generation
Venom immunogens. Twelve venoms were sourced from a wide geographical and taxo-
nomic diversity of snake species known to cause potent haemotoxicity in snakebite victims
(Table 1). Many of these venoms were collected from animals maintained under controlled
environmental and dietary conditions in the UK Home Office licensed and inspected herpe-
tarium of the Centre for Snakebite Research and Interventions (CSRI) at the Liverpool School
of Tropical Medicine. The remainder were sourced from historical venom collections held in
the CSRI herpetarium or commercially purchased from Latoxan, France. Lyophilised venoms
were stored at 4˚C and reconstituted with phosphate-buffered saline (PBS) (0.12 M NaCl, 0.04
M phosphate, pH 7.2) to a concentration of 1 mg/ml prior to use. The same batches of these
venoms were used for each of the analyses to provide cross-experimental continuity.
Ovine immunisation. Two different venom mixtures were prepared as immunogens for
antivenom generation. For each immunogen mixture, 3 mg of each venom was weighed and
mixed manually in glass bijous, with immunogen mixture I consisting of seven procoagulant
venoms from key medically important and/or geographically and taxonomically diverse snake
species and mixture II consisting of the same seven venoms plus five additional haemotoxic
venoms from snakes of secondary experimental importance (Table 1). The resulting mixtures
were then reconstituted with PBS to a concentration of 1 mg/ml for immunisation. Ovine
Table 1. The venoms used in the immunisation mixtures for the generation of experimental antivenoms (EAVs).
Species Sub-family Geographical region Venom origin
Immunogen mixture I (resulting in EAV 1) Bothrops asper Crotalinae Central America Costa Rica
Bothrops jararaca Crotalinae South America Brazil
Echis ocellatus Viperinae West Africa Nigeria
Calloselasma rhodostoma Crotalinae Southeast Asia Captive bred
Dispholidus typus Colubrinae sub-Saharan Africa South Africa�
Deinagkistrodon acutus Crotalinae East Asia Captive bred
Daboia russelii Viperinae South Asia Sri Lanka
Immunogen mixture II (resulting in EAV 2) The same 7 venoms in immunogen mixture I plus:
Bitis arietans Viperinae sub-Saharan Africa Nigeria
Echis carinatus Viperinae Middle East & South Asia India��
Rhabdophis subminiatus Natricinae Southeast Asia Hong Kong
Trimeresurus albolabris Crotalinae Southeast Asia Captive bred
Crotalus atrox Crotalinae North America USA
� venom sourced commercially from Latoxan, France
�� Indian Echis carinatus sochureki venom (referred to as Echis carinatus throughout) was collected from a single specimen that was inadvertently imported to the UK
via a boat shipment of stone, and then rehoused at LSTM on the request of the UK Royal Society for the Prevention of Cruelty to Animals (RSPCA).
https://doi.org/10.1371/journal.pntd.0009659.t001
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immunisation was performed by Ig-Innovations (Wales, UK) under licensed approval of the
UK Home Office and in accordance with the UK Animal [Scientific Procedures] Act 1986,
with n = 1 per immunogen group. Each sheep was initially immunised with equal quantities of
an emulsion comprised of the venom mixtures (0.5 mg) and Freund’s Complete Adjuvant.
Subsequent immunisations consisted of an emulsion of the venom mixtures (1.0 mg) and
Freund’s Incomplete Adjuvant (1:1, volume/volume). Immunisations were performed every
four weeks until 42 weeks. Low volume blood samples (~5 ml) were collected two weeks after
each immunisation to monitor seroconversion over the immunisation time course, and at the
end of the immunisation schedule (i.e. 42 weeks), a larger blood volume (~300 ml) was col-
lected, and sera collected post-centrifugation for downstream IgG purification. Sera were
stored long term at -20˚C.
Immunoglobulin purification. For the purification of IgG from ovine serum [21], each
of the 42-week serum samples (and a pre-immunisation sample to serve as a normal ovine IgG
control) were first diluted with 0.90% saline (1:1 ratio), before the slow (drop by drop) addition
of caprylic acid (Octanoic acid; Sigma, UK) with stirring to a final concentration of 6%. Subse-
quently, non-immunoglobulin proteins were precipitated by vigorous stirring for 60 minutes,
followed by centrifugation at 12,800 x g for 60 min at 4˚C. The resulting supernatant from
each sample was dialysed separately using 35 mm 3.5K MWCO SnakeSkin Dialysis Tubing
(Thermo-Fisher Scientific, UK) and sodium citrate buffered saline (SCS, pH 6.0), with two
changes of SCS, first at room temperature (RT) for one hour, and then secondarily at 4˚C over-
night. Following dialysis, the final IgG samples were lyophilised using a Labogene lyophiliser
and stored as a powder at 4˚C prior to reconstitution in PBS. The resulting experimental anti-
venoms (EAV) were thereafter denoted as EAV 1 (generated from immunogen mixture I) and
EAV 2 (generated from immunogen mixture II). For downstream testing, these EAVs were
studied in comparison with the positive control antivenom used, the equine-derived SAIMR
polyvalent antivenom (South African Vaccine Producers (PTY) Ltd, Gauteng, South Africa,
expiry date: 11/2017, Lot#: BF00546, concentration 107 mg/ml), raised via immunisation with
venom from Bitis arietans, Bitis gabonica,Hemachatus haemachatus, Dendroaspis angusticeps,
Dendroaspis jamesoni, Dendroaspis polylepis, Naja nivea, Naja melanoleuca, Naja annulifera
and Naja mossambica.
In vitro immunological assays
SDS-PAGE gel electrophoresis and immunoblotting. For gel electrophoresis, 15 well
15% SDS-PAGE gels were prepared using the following approach: resolving gel (3.75 ml H2O,
2.5 ml Tris pH 8.8 [1.5 M], 3.75 ml 40% bis-acrylamide, 100 μl 10% SDS, 60 μl 10% ammonium
persulfate [APS] and 7 μl N,N,N0,N0-Tetramethyl ethylenediamine [TEMED]); stacking gel
(2.5 ml H2O, 1 ml Tris pH 6.8 [1 M], 350 μl 40% bis-acrylamide, 30 μl 10% APS and 5 μl
TEMED). Next, 10 μl of each venom (1 mg/ml) was mixed 1:1 volume/volume with reducing
buffer (150 μl β-mercaptoethanol and 850 μl of the following buffer mixture: 1.25 ml Tris pH
6.8 [0.5 M], 2.50 ml glycerol, 2.0 ml 10% SDS, 1.50 ml saturated Bromophenol blue) and subse-
quently heated for 10–15 minutes at 100˚C. Thereafter, 10 μl of each venom/buffer sample was
added to the gel, alongside 5 μl of a molecular weight protein marker (Broad Range Molecular
Marker, Promega), and the samples run at 200 V for 55 minutes using a Mini-PROTEAN Elec-
trophoresis System (Bio-Rad). Resulting gels were then stained at a final concentration of 0.1%
(w/v) Coomassie blue R350 (0.4 g of Coomassie blue R350 in 200 mL of 40% [v/v] methanol in
H2O, 10% (v/v) glacial acetic acid and 20% (v/v) methanol) overnight at RT. Gels were
destained (4:1:5 methanol:glacial acetic acid:H2O) for at least 2 hours at RT. For visualisation,
gels were subsequently imaged using a Gel Doc EZ Gel Documentation System (Bio Rad).
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For immunoblotting, SDS-PAGE gel electrophoresis was performed as described above,
but instead of Coomassie staining, proteins in the gels were transferred onto 0.2 μm nitrocellu-
lose membranes using a Trans-Blot Turbo Transfer System (Bio-Rad). Following confirmation
of protein transfer by reversible Ponceau S staining, the membranes were blocked for non-spe-
cific binding using 5% non-fat dried milk in TBST (0.15 M NaCl; 0.01 M Tris-HCl, pH 8.5; 1%
Tween 20), and left overnight at 4˚C rocking at slow speed. Subsequently, blots were washed
three times over 15 minutes with TBST, before the addition of primary antibodies (either:
EAV 1 or EAV 2, the negative control [pre-immunisation, naïve ovine IgG] or the positive
control [SAIMR polyvalent antivenom]), with all primary antibodies standardised to an initial
concentration of 50 mg/ml, and then diluted to 1:5,000 in 5% non-fat dried milk in TBST, and
incubated for 2 hours at RT. The immunoblots were then washed in triplicate with TBST as
described above and incubated for two hours at RT with 50 ml of appropriate secondary anti-
bodies diluted 1:2,000 in PBS: (i) horseradish peroxidase-conjugated donkey anti-sheep IgG
(Sigma, UK) for the two EAVs and the ovine IgG control and (ii) horseradish peroxidase-con-
jugated Rabbit anti-horse IgG (Sigma, UK) for the SAIMR Polyvalent positive control anti-
venom and the equine IgG control. The immunoblots were then washed again with TBST and
developed by the addition of DAB substrate (50 mg 3,3’- 222 diaminobenzidine, 100 ml PBS
and 0.024% hydrogen peroxide; Sigma) by placing the membrane into the substrate for 30 sec-
onds, before washing with deionised water.
End-point titration by enzyme-linked immunosorbent assay (ELISA). Microtiter 96
well ELISA plates (Thermo Fisher Scientific) were coated with coating buffer (100 mM carbon-
ate/Bicarbonate buffer, pH 9.6) containing 100 ng of each venom or each venom immunogen
mixture and incubated overnight at 4˚C. The plates were then washed three times with TBST
before the addition of 5% non-fat milk in TBST and incubated at RT for two hours, followed
by washing another three times with TBST. Next, 120 μl of primary antibodies (as described
for immunoblotting experiments) were added to the plate in duplicate at an initial dilution of
1:100 in 5% non-fat milk in TBST, followed by five-fold serial dilutions across the plate and
incubation at 4˚C overnight. The plates were then washed again with TBST and incubated for
two hours at RT with appropriate secondary antibodies (as per immunoblotting experiments)
diluted at 1:1,000 in PBS. The plates were then washed again with TBST before the addition of
substrate (0.2% 2,2/-azino-bis[3-ethylbenzthiazoline-6-sulphonic acid]) in citrate buffer (0.5
M, pH 4.0) containing 0.015% hydrogen peroxide (Sigma, UK). Plates were gently mixed and
incubated at RT for 15 mins, before the signal was read spectrophotometrically at 405 nm on a
FLUOstar Omega microplate reader (BMG LabTech).
Relative avidity by ELISA. Relative avidity ELISAs were performed as per the end point
titration ELISA assays, except that: (i) the primary antibodies were incubated at a single
defined dilution (1:10,000) and (ii) after washing the primary antibody with TBST, wells were
exposed to the chaotropic agent, ammonium thiocyanate (NH4SCN), at a range of concentra-
tions (0–8 M) in duplicate for 15 minutes at RT [24]. The plates were then washed with TBST,
and all subsequent steps were the same as described for the end point titration ELISA. To per-
mit direct and informative comparisons, reduction percentages (in terms of OD values) were
calculated by subtracting 4 M NH4SCN readings from 0 M readings (the control) and multi-
plying by 100.
In vitro functional assays
Serine protease assay. To quantify venom serine protease activity and inhibition by the
EAVs, we used a chromogenic kinetic enzymatic assay [43]. One microgram (1 mg/ml) of
each venom and 10.6 μg (70 mg/ml) of the two EAVs or the commercial antivenom (SAIMR
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polyvalent) were co-incubated in a water bath at 37˚C for 30 min. This incubation time (and
as used for other assays below) was selected to match the venom-antivenom incubation times
conventionally applied across preclinical antivenom efficacy studies (see later). For determin-
ing baseline venom activity, we replaced antivenom with PBS, to act as a venom only control.
A positive control venom with known serine protease activity was also used for standardisation
across assays (1 μg; B. arietans [43]), alongside a PBS (no venom) negative control. Each sam-
ple was added in triplicate to a 384-well microplate (Greiner). The plate was then incubated
for 3 min at 37˚C in a FLUOstar Omega microplate reader (BMG Labtech). Next, 15 μl of
buffer (100 mM Tris, pH 8.5, 100 mM NaCl) was overlaid using a pipetting robot (Multidrop,
Thermo Scientific) and the plate incubated for a further 3 min at 37˚C. Finally, 15 μl of 6 mM
chromogenic substrate (S-2288, Cambridge Bioscience) at a final concentration of 2 mM was
added. The enzymatic reaction was then monitored kinetically for 60 cycles (30 sec. each; ~30
min total) using a FLUOstar Omega microplate reader (BMG Labtech), with a temperature
setting of 37˚C and using a wavelength of 405 nm. Mean measures of absorbance were plotted
against time to compare venom activity with baseline (negative controls) and positive control
readings. For quantification, we first calculated the mean rates (expressed as ΔAbs/time/μg
venom) of at least triplicate readings by subtracting negative control readings (PBS) from each
reading. The rate of substrate consumption was calculated by subtracting the 0 min readings
from the 5 min readings and then dividing by 5 min. Finally, the reduction percentage for all
antivenom samples was calculated by subtracting the mean of the relevant negative control
readings from the venom readings. The resulting triplicate readings were then plotted with
standard error of the means (SEMs).
Metalloproteinase assay. To quantify snake venom metalloproteinase activity and inhibi-
tion by the EAVs, we used a fluorescent kinetic enzymatic assay [44]. The SVMP assay kineti-
cally measured cleavage of a quenched fluorogenic substrate (ES010, R&D Biosystems) by
venom in the presence or absence of inhibitors. One microgram (1 mg/ml) of each venom and
6.91 μg (70 mg/ml) of the two EAVs or the commercial antivenom (SAIMR polyvalent) were
co-incubated in a water bath at 37˚C for 30 min. For determining baseline venom activity, we
replaced antivenom with PBS, to act as venom only controls. A positive control venom with
known metalloproteinase activity was also used for standardisation across assays (1 μg; E. ocel-
latus [44]), alongside a PBS (no venom) negative control. Ten microlitres of each sample was
then added in triplicate to a 384-well microplate (Greiner) followed by the addition of 90 μl of
the substrate (10 μl of the substrate [supplied as a 6.2 mM stock] was used per 5 ml reaction
buffer [50 mM Tris-Cl pH 7.5, 150 mM NaCl] at a final substrate concentration of 10 μM), to
all samples using a multichannel pipette. The assay was then read kinetically for 1 hour at 25˚C
using a FLUOstar Omega microplate reader (BMG Labtech) and an excitation wavelength of
320 nm and an emission wavelength of 405 nm. The enzymatic reaction was monitored by set-
ting the gain adjustment on the instrument to 5% in wells where high activity was expected
(e.g., positive control/venom only mixtures). Mean measures of absorbance were then plotted
against time to compare venom activity with baseline (negative controls) and positive control
readings. For quantification, we calculated areas under the curves (AUCs) and the standard
error of mean AUCs readings for each sample in the 0–40 min interval, this time point was
chosen as the time where all fluorescence curves had reached a plateau (maximum fluores-
cence). We then subtracted the mean of the relevant negative control readings from the venom
readings and calculated the reduction percentage for all antivenom samples and plotted the
triplicate readings with SEMs.
Plasma coagulation assay. To quantify venom coagulotoxicity and inhibition by the
EAVs, we used a kinetic absorbance-based coagulation assay [45]. One microgram (100 ng/μl)
of each venom and 3.75 μg (70 mg/ml) of the two EAVs or the commercial positive control
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antivenom (SAIMR polyvalent) were co-incubated in a water bath at 37˚C for 30 min. The
positive control used was 1 μg of E. ocellatus venom based on its potent procoagulant effect in
this assay [44], and the negative control was plasma with the addition of PBS instead of venom.
During sample incubation, bovine plasma (sterile filtered, Biowest, Nuaille, France) was
defrosted and centrifuged for 4 min at 805 x g to remove precipitate prior to use. Following
incubation, 10 μl of each venom-antivenom mixture was added to a 384 well microplate (Grei-
ner), followed by the addition of 20 μl of 20 mM CaCl2 (prepared fresh for each assay), and
finally 20 μl of the citrated bovine plasma. The plates were loaded using a multidrop pipetting
robot (Multidrop Labsystems) and resulting clotting data were captured kinetically for 2 hours
using a FLUOstar Omega microplate reader (BMG Labtech) at OD 595 nm and 25˚C. Mean
measures of absorbance were plotted against time to compare venom activity with baseline
(negative controls) and positive control readings. For quantification, we calculated the AUCs
and the standard error of the mean AUCs. We then subtracted the mean of the relevant nega-
tive control readings from the venom readings and calculated the reduction percentage of
venom activity for all datasets with SEMs.
In vivo efficacy assays
In vivo venom median lethal dose. To assess the preclinical efficacy of the EAVs, we used
modified versions of established murine models of envenoming [44] and selected a sub-set of
the venoms used as immunogens, along with two additional venoms not used as immunogens,
to assess the breadth of antivenom paraspecific efficacy against haemotoxic snakebite. As an
essential prerequisite to preclinically assessing antivenom efficacy, World Health Organiza-
tion-recommended protocols were used to determine the median murine lethal dose (LD50) of
various snake venoms via the intravenous route [44]. For these studies, we selected four ven-
oms used as immunogens for generating both EAVs (Bothrops asper, Calloselasma rhodos-
toma, E. ocellatus and Daboia russelii) and two venoms used as immunogens only for
generating EAV 2 (B. arietans and Echis carinatus). We also used venom from two species of
snake not used as venom immunogens for either EAVs to assess their paraspecific neutralisa-
tion capabilities, specifically Vipera ammodytes (captive bred) and Lachesis muta (Brazil).
Existing LD50 data was available for six of the eight venoms used (Table 2) and, for each of
these six venoms, the described LD50 data had previously been applied to the same venom
samples as those used in this study in other studies previously conducted by the authors
[43,44,46] Therefore, LD50 experiments were only performed for venom samples from C. rho-
dostoma and L.muta, as these had not previously been utilised for in vivo research. All experi-
mental animals (4–5 weeks old, 18–20 g, male, CD-1 mice, Charles River, UK) were housed in
groups of five with environmental enrichment, water and food ad libitum and their health
monitored daily during acclimatisation. Each animal received an iv tail injection of varying
Table 2. The murine intravenous median lethal dose (LD50) of the haemotoxic snake venoms used in this study.
Species Venom origin LD50 (μg/mouse) 95% confidence intervals (μg) Reference
Bothrops asper “Atlantic”, Costa Rica 18.8 (15.6–22.0) [61]
Calloselasma rhodostoma Thailand 31.2 (20.6–47.2) This study
Echis ocellatus Nigeria 20.1 (17.3–22.8) [62]
Daboia russelii Sri Lanka 7.8 (7.0–8.6) [63]
Bitis arietans Nigeria 21.6 (20.0–29.0) [48]
Echis carinatus India 19.0 (16.0–24.0) [48]
Vipera ammodytes Captive bred 8.0 (7.5–8.5) [46]
Lachesis muta Brazil 6.8 (5.4–8.5) This study
https://doi.org/10.1371/journal.pntd.0009659.t002
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doses of venom in 100 μl PBS, and experimental animals were monitored for 6 hours after
injection, with the number of surviving mice in each group recorded. Experimental animals
were euthanised on ethical grounds via rising concentrations of CO2 if they exhibited signs of
humane end points that are predicators of lethality (e.g., pulmonary distress, immobility, sei-
zure, haemorrhage, paralysis) [44]. The resulting LD50 values and 95% confidence intervals
were generated based on dose and mortality data using Probit analysis [47].
In vivo antivenom efficacy. To assess the efficacy of the EAVs at protecting experimental
animals from the lethal effects of envenoming, we used a modified version of the median effec-
tive dose (ED50) assay [48]. For each of the eight venoms, the procedure consisted of groups of
five mice (4–5 weeks old, 18–20 g, male, CD-1 mice, Charles River, UK; maintained as
described above) receiving an iv tail injection of either: (i) 5 x LD50 dose of venom only, or 5 x
LD50 dose of venom preincubated for 30 mins at 37˚C with 100 μl (5 mg) of (ii) EAV 1, (iii)
EAV 2 or (iv) SAIMR polyvalent (as a positive control) antivenom. Antivenom concentrations
were standardised to 50 mg/ml prior to use, and all final injected doses were made up to 200 μl
using PBS (0.12 M NaCl, 0.04 M phosphate, pH 7.2). As detailed above, experimental animals
were monitored for signs of suffering for 6 hours, with euthanasia applied via the implementa-
tion of the described humane endpoints where necessary, and the number of deaths, time of
euthanasia and survivors in each group recorded throughout the experiment. This monitoring
window was selected to capture protection against acute venom toxicity, and applied based on
animal ethical grounds to reduce the duration of severe suffering imposed on experimental
animals during envenoming experiments. Thereafter, Kaplan–Meier survival graphs were
used to visualise the relative preclinical protection provided by the antivenoms against each of
the venoms.
Statistical analyses
To statistically test whether the EAVs inhibited the in vitro activity of each venom in the serine
protease, metalloproteinase and plasma clotting assays we compared mean readings with
venom only control readings using one-way ANOVA (with Dunnett’s multiple comparisons
test) and a significance threshold of (P�0.05). All statistical analyses were performed using
Prism v8 software (GraphPad).
Results
Monitoring seroconversion during immunisation
To assess the specificity of the immune response towards the venom immunogens over the
course of the immunisation period, serum samples were collected every four weeks and
assessed via ELISA to quantify antibody binding levels. Both sheep responded in a highly simi-
lar manner to the different immunogen mixtures (see Table 1 for details of immunogens),
with rapid increases in antibody binding levels observed following primary immunisation, fol-
lowed by a short plateau in antibody titres and then secondary increases (Fig 1). For both
immunised animals, serum samples collected at the end of the immunisation schedule (week
42) exhibited the highest antibody binding titres (Fig 1). These samples were subsequently sub-
jected to IgG extraction for preparation of EAV 1 and EAV 2.
Immunological cross-reactivity of the experimental antivenoms
To visualise the immunological recognition of the two EAVs against the venom proteins
found in the 12 venoms used in the immunisation process, we subjected each venom and each
venom immunogen mixture to reduced SDS-PAGE gel electrophoresis and western blotting.
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As anticipated, the reduced SDS-PAGE profiles illustrated considerable inter-specific variation
in the molecular weights and relative abundances of the different proteins found in the various
venoms (Fig 2A). Immunoblotting experiments with each of the EAVs revealed extensive
immunological recognition of the proteins found in each of the snake venoms and the two
immunising mixtures, despite EAV 1 being generated with only seven of the 12 venoms used
as immunogens to generate EAV 2 (Fig 2C and 2D). However, despite these broad similarities,
these experiments revealed that EAV 1 exhibited some reductions in binding intensity com-
pared with EAV 2, and also did not recognise the low molecular weight components (i.e., 10–
15 kDa) of D. typus and R. subminiatus venoms to the same extent as EAV 2. As anticipated,
both EAVs exhibited increases in venom recognition compared with the SAIMR polyvalent
antivenom (positive control, and for which only B. arietans is an immunogen; Fig 2B) and the
normal horse and sheep negative controls (Fig 2E and 2F).
Next, we used end-point titration ELISAs to quantify the binding between the EAVs and
the various venom immunogens. Comparisons of the binding titres of each EAV revealed
highly comparable levels to each of the individual venoms used as immunogens (Figs 3A and
S1), despite five additional venoms being added to the immunogen mixture used to raise EAV
2. An exception to this was that EAV 2 exhibited considerably highly titres to the venom of R.
subminiatus than EAV 1 (Figs 3A and S1). This finding is consistent with the presence of this
venom only being in the immunising mixture used to raise EAV 2, though, interestingly, no
such differences were observed with the other four venoms unique to this immunogen mixture
(i.e. B. arietans, E. carinatus, Trimeresurus albolabris and Crotalus atrox). Secondly, and per-
haps surprisingly, we observed substantial increases in immunological binding to immunogen
mixture II with EAV 1, rather than EAV 2 (Figs 3A and S2A). When comparing the levels of
immunological cross-reactivity from the venom perspective, we observed considerable varia-
tion in binding levels, with six venoms exhibiting high titres, five with more moderate levels of
binding and perhaps the most noticeable finding being that only low levels of binding were
observed between C. rhodostoma venom and both EAVs (Figs 3A and S1).
Fig 1. Time course analysis of the immunological cross-reactivity of ovine serum to the immunogen mixtures over 42 weeks of
immunisation. A) Responses of EAV 1 against immunogen mixture I (containing seven venoms) and B) responses of EAV 2 against
immunogen mixture II (containing 12 venoms). All sheep serum samples were standardised to 50 mg/ml prior to a 1:1,000 dilution for
use and compared with a variety of appropriate controls: normal IgG sourced from non-immunised sheep and horses, the commercial
equine antivenom SAIMR polyvalent and a PBS (no venom) negative control. Data points represent means of duplicate readings and
error bars represent standard deviation (SD) of the duplicate measurements.
https://doi.org/10.1371/journal.pntd.0009659.g001
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To determine the strength of these antibody-venom protein binding interactions we per-
formed avidity ELISAs, which consisted of quantifying venom-antibody binding levels in the
presence of increasing concentrations of a chaotropic agent (ammonium thiocyanate,
NH4SCN; 0-8M) that disrupts antibody-antigen binding. The results revealed that both EAVs
Fig 2. SDS-PAGE gel electrophoretic profiles of the individual venoms and the venom immunogen mixtures and their
immunological recognition by experimental antivenoms. A) Venoms were separated by reduced SDS-PAGE gel electrophoresis and
visualised by Coomassie blue staining. The same venom samples were transferred to nitrocellulose membranes for immunoblotting, and
incubated with 1:5,000 dilutions of SAIMR polyvalent antivenom (positive control) (B), EAV 1 (C), EAV 2 (D), normal horse IgG (E)
and normal sheep IgG (F) (both negative controls). PM indicates protein marker.
https://doi.org/10.1371/journal.pntd.0009659.g002
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exhibit highly comparable, and potent, binding to the two venom mixtures and to each indi-
vidual venom used as an immunogen, even in the presence of up to 4M ammonium thiocya-
nate (Figs 3B, S2B and S3). For the vast majority of venoms, the binding reductions observed
at 4M concentrations of the chaotrope were less than 20% of those observed with the control
(no chaotrope). The exception to this was the venom of C. rhodostoma, which, as also observed
in the end-point ELISA experiments, exhibited lower binding levels with both EAV 1 and
EAV 2, and resulted in percentage reductions of 35% and 30%, respectively (Figs 3B and S3).
Comparisons between EAV 1 and EAV 2 revealed very little difference in avidities across the
individual venoms and the venom immunogen mixtures, though in general EAV 2 exhibited
slightly lower reductions in antibody binding in the presence of the chaotrope compared with
EAV 1 (Figs 3B, S2B and S3).
In vitro venom neutralisation by the EAVs
While high levels of immunological binding appear to be a prerequisite for antivenom efficacy,
immunological binding does not necessarily result in toxin neutralisation. To assess the capa-
bility of the EAVs to neutralise venom functional activities related to haemotoxicity, we
employed three different in vitro functional screening assays, which specifically related to
SVSP, SVMP and coagulotoxic venom activities.
The results of our kinetic chromogenic SVSP assay revealed that seven of the 12 venoms
tested, and both of the venom immunogen mixtures, exhibited considerable SVSP activity as
evidenced by substantial increases in the rate of substrate cleavage compared to the negative
control (Figs 4A and S4). These venoms included three used as venom immunogens for both
EAVs (B. asper, Bothrops jararaca, E. ocellatus) and four used only to raise EAV 2 (B. arietans,
Fig 3. A comparative summary of the immunological binding observed between the two experimental antivenoms and the
individual venoms and venom immunogen mixtures as measured by end-point and avidity ELISA. A) A summary of the
immunological binding observed by end-point titration ELISA. The data displayed represents the mean optical density following the
addition of primary antibodies at 1:1000 dilution. See S1 and S2A Figs for full binding profiles generated using fivefold titrations. B) A
summary of the immunological binding observed by avidity ELISA. The data displayed represents the mean percentage reduction in
antibody binding levels for each venom measured in the presence of 4M and 0M (control) ammonium thiocyanate. See S2B and S3 Figs
for full binding profiles at increasing concentrations of the chaotrope (0-8M). For both sets of experiments, the primary antibodies
consisted of EAV 1 and EAV 2, the commercial SAIMR polyvalent antivenom positive control, and normal sheep and horse IgG as
negative controls. Error bars represent SD of duplicate measurements.
https://doi.org/10.1371/journal.pntd.0009659.g003
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Fig 4. The in vitro venom activity of the venom immunogens and quantification of venom neutralisation by the experimental
antivenoms. A) The serine protease (SVSP) activity of individual venoms and the venom immunogen mixtures displayed as the rate of
cleavage (absorbance/time) of the chromogenic substrate. B) Inhibition of venom serine protease activities by the EAVs displayed as the
percentage reduction of venom only activities from (A). Also see S2C and S4 Figs. C) The metalloproteinase (SVMP) activity of
individual venoms and the venom immunogen mixtures displayed as the area under the curve (AUCs) resulting from cleavage of a
fluorescent substrate over time. D) Inhibition of venom metalloproteinase activities by the EAVs displayed as the percentage reduction
of venom only activities from (C). See also S2D and S5 Figs. E) The coagulopathic activity of individual venoms and the venom
immunogen mixtures displayed as the AUCs resulting from increases in absorbance stimulated by clotting over time. F) Inhibition of
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E. carinatus, T. albolabris and C. atrox). Consequently, we noted that venom immunogen mix-
ture II exhibited increased SVSP activity compared with mixture I (Figs 4A and S2C). The
other venoms had little to no SVSP activity at the concentration tested, and thus were not used
in subsequent neutralisation experiments using the EAVs. Neutralisation of SVSP activity at
the tested antivenom concentration showed a variable pattern across the venoms, with EAV 2
exhibiting high percentage reductions (>50% of venom only activity) against four of the seven
individual venoms tested, but had no effect on B. asper or B. arietans venom, and only resulted
in minor reductions against B. jararaca (Figs 4B and S4). Contrastingly, EAV 1 only exhibited
high levels of SVSP inhibition against B. arietans and T. albolabris–a surprising result since
neither of these venoms were included in the immunogen mixture used to generate this EAV
(Figs 4B and S4). More moderate reductions (20–30%) in SVSP activity were observed for four
of the remaining venoms. Despite these observations, both EAVs exhibited highly comparable
inhibition of the SVSP activity of the two immunogen mixtures, and though neither neutral-
ised the venom activity to control readings, both exhibited significant inhibition (P�0.05 for
all comparisons vs venom only controls, one-way ANOVA), resulting in >60% reductions in
SVSP activity (Figs 4B and S2C).
The enzymatic SVMP activities of the venoms used in this study were quantified via a
kinetic, fluorescent assay. The majority of the 12 venom immunogens exhibited detectable
SVMP activity, with the exceptions being those from R. subminiatus, T. albolabris andD. russe-
lii (Figs 4C and S5). The latter finding is perhaps surprising given that a potent Factor X acti-
vating SVMP is known to be present in D. russelli venom [13], suggesting that this result may
perhaps be a reflection of limitations in substrate specificity. Nonetheless, SVMP inhibition
studies against the remaining nine venoms revealed that both EAVs exhibited considerable
neutralising capability, with between 40–80% of the venom SVMP activity reduced across the
various venoms (Figs 4D and S5). Detailed comparisons between both EAVs revealed highly
similar percentage reductions in SVMP activity for six of the nine venoms tested (B. asper, D.
typus, Deinagkistrodon acutus, B. arietans, E. carinatus and C. atrox), while EAV 1 exhibited
modest increases in inhibitory potency against B. jararaca (80.2% reduction in venom only
activity), though EAV 2 slightly outperformed EAV 1 against E. ocellatus venom (83.3% vs
70.1% reduction, respectively) (Figs 4D and S5). Interestingly, the SAIMR polyvalent control
antivenom outperformed both EAVs in inhibiting B. arietans and C. atrox venoms, though the
former of these two venoms is used as an immunogen during the generation of this product.
This control antivenom also exhibited comparable SVMP neutralising capabilities to the EAVs
against D. acutus and D. typus venoms, though it was much less effective against B. asper and
E. ocellatus (Figs 4D and S5). Against the two immunogen mixtures, all three antivenoms
tested exhibited significant reductions in venom activity compared with control readings
(P�0.05 for all comparisons vs venom only controls, one-way ANOVA). While there was little
difference between the levels of inhibition observed between EAV 2 and the SAIMR polyvalent
control antivenom, EAV 1 outperformed both comparators, resulting in percentage reductions
of 75.9% and 57.1% of SVMP activity for immunogen mixture I and II, respectively (vs 57.7%
and 41.5% for EAV 2) (Figs 4D and S2D).
To assess the coagulopathic activity of the venom immunogen mixtures and their constitu-
tive venoms, we used an absorbance-based plasma clotting assay. Nine of the 12 venom immu-
nogens and both venom mixtures exhibited potently procoagulant activities with an additional
venom (C. atrox) exhibiting moderate procoagulant activity, as evidenced by increases in
coagulopathic venom activities by the EAVs displayed as the percentage reduction of venom only activities from (E). See also S2E and S6
Figs. For all data shown, data points represent means of triplicate readings, and error bars represent standard error of the mean (SEMs).
https://doi.org/10.1371/journal.pntd.0009659.g004
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kinetic profiles compared with the negative control (Figs 4E and S6). Neither B. arietans nor T.
albolabris exhibited potent coagulopathic activity in this assay at the concentration tested.
Neutralisation experiments with the two EAVs revealed marked inhibition of the coagulo-
pathic toxins found in the majority of the coagulopathic venom immunogens (Figs 4F and S6).
With the exception of C. atrox, EAV 1 reduced the procoagulant activity of the other nine ven-
oms tested by 50–70%, including a number of venoms not used as immunogens to raise this
antivenom (e.g. R. subminiatus and E. carinatus) (Figs 4F and S6). The results observed with
EAV 2 were highly comparable to those of EAV 1 (percentage reductions of 50–70% for eight
of the ten tested venoms), although in addition to a comparable lack of inhibition against C.
atrox, EAV 2 also lacked inhibitory potency against the venom of E. ocellatus (percentage
reduction of 20%), despite this venom being included in the immunising mixture (Figs 4F and
S6). Both venom immunogen mixtures were also found to be potently procoagulant, and this
venom activity was effectively neutralised by both EAV 1 and EAV 2, although inhibition was
greatest with EAV 1, irrespective of the venom immunogen mixture (75.9% reduction vs
57.7% against immunogen mixture I; 57.1% vs 41.5% against immunogen mixture II) (Figs 4F
and S2E). However, despite neither EAV by itself affecting normal coagulation, the addition of
EAV 1 in the presence of the two venom immunogen mixtures resulted in a delay of clotting,
and therefore net anticoagulant activity (S2E Fig). The reason for this remains unclear, but
might indicate potent inhibition of procoagulant venom toxins, but ineffective inhibition of
anticoagulant venom toxins, as seen elsewhere [43]. Contrastingly, EAV 2 effectively inhibited
venom immunogen stimulated coagulation to control levels, though this same phenomenon
was observed for both EAVs against many of the individual venom immunogens (S6 Fig). The
SAIMR polyvalent antivenom was ineffective against all of the individual venoms and venom
immunogen mixtures tested, likely as the result of no procoagulant snake venoms being used
as immunogens during the production of this product (Fig 4F).
In vivo neutralisation of venom lethality
Following promising evidence of in vitro immunological cross-reactivity and venom neutrali-
sation with the two EAVs, we next assessed their preclinical efficacy against a subset of haemo-
toxic venoms using a variation of the World Health Organization-recommended assay for
assessing antivenom efficacy, the murine median effective dose [49]. We selected eight venoms
for preclinical assessment; four that were included in both venom immunogen mixtures (B.
asper, C. rhodostoma, E. ocellatus and D. russelii), two that were only included in the immuno-
gen mixture used to generate EAV 2 (B. arietans and E. carinatus) and, to assess whether the
breadth of antibodies generated by the diverse immunogen mixtures stimulated broad para-
specific efficacy, two haemotoxic venoms that were not used in either immunogen mixture (V.
ammodytes and L.muta) (Table 2). Prior to performing antivenom efficacy experiments, the
LD50 of L.muta and C. rhodostoma venoms were determined, resulting in LD50s of 6.8 μg/
mouse (95% confidence intervals: 5.40–8.54 μg/mouse) and 31.2 μg/mouse (20.6–47.2 μg/
mouse), respectively. The LD50s for the remaining species were sourced from previously pub-
lished studies (Table 2). Thereafter, groups of five mice were dosed with 5 x LD50 dose of
venom only, or 5 x LD50 dose of venom preincubated for 30 mins at 37˚C with 100 μl (5 mg)
of either EAV 1 or EAV 2, or the control SAIMR polyvalent antivenom (all were standardised
to 50 mg/ml).
Our dose-matched pilot in vivo findings demonstrated that, despite a reduction in the num-
ber of venoms used in the immunogen mixture (7 vs 12), EAV 1 outperformed EAV 2 in
terms of preclinical efficacy (superior vs four venoms; equipotent vs two venoms; inferior vs
one venom) (Fig 5). Indeed, EAV 1 effectively prevented venom-induced lethality for the
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duration of the experiment against three of the four venoms used as immunogens (B. asper, E.
ocellatus and D. russelii), and two of the four venoms tested that were not present in the immu-
nising mixture (B. arietans and V. ammodytes) in this model (Fig 5). Contrastingly, none of
the venoms present in the immunogen mixture used to raise EAV 2 were fully neutralised (i.e.
conferred complete protection, 100% survival) by this EAV, though four of the five experimen-
tal animals survived the challenge dose with B. asper, B. arietans and E. carinatus venom (Fig
5). The result with this latter venom proved to be the only example of superior preclinical effi-
cacy exhibited by EAV 2 over EAV 1 (four vs one survivor, respectively). Disappointingly,
EAV 2 exhibited limited/no protection against envenoming by E. ocellatus and D. russelii–
arguably the two most medically-important species tested (Fig 5). Both EAVs exhibited
Fig 5. Kaplan–Meier survival curves for murine preclinical efficacy experiments using representative, geographically diverse,
haemotoxic snake venoms and the experimental antivenoms. Groups of five mice were challenged intravenously with 5 x LD50 doses
of each venom (purple lines) or venom preincubated for 30 min at 37˚C with EAV 1 (blue) or EAV 2 (red), or the SAIMR polyvalent
control antivenom (green). All experimental animals were monitored for 6 hours and survival times recorded. All antivenom doses were
standardised to 5 mg (100 μl, 50 mg/ml).
https://doi.org/10.1371/journal.pntd.0009659.g005
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comparable, limited protection against the lethal effects of C. rhodostoma venom (two of five
experimental animals survived the duration of the experiment), which correlates with our ear-
lier observations of reduced immunological cross-reactivity to the toxins found in this venom
(see Fig 3), and suggests that higher therapeutic doses than tested here are likely required to
provide full protection. Identical and contrasting efficacy observations were also observed in
respect of the remaining two venoms tested, neither of which was used as an immunogen to
generate either EAV; both antivenoms failed to provide any protection against the lethal effects
of L.muta venom, though both EAVs exhibited potent paraspecific preclinical efficacy against
V. ammodytes (Fig 5). To place these findings into context, we compared our preclinical effi-
cacy data against that obtained using our antivenom control, SAIMR polyvalent, which is
manufactured using venom from a variety of African vipers and elapids as immunogens. As
anticipated, both EAVs outperformed SAIMR polyvalent, with only EAV 1 proving inferior
against the lethal effects of E. carinatus venom, while EAV 2 was only outperformed in experi-
ments using E. ocellatus and B. arietans venoms (Fig 5).
Discussion
There are a number of major obstacles that need to be tackled to ensure the effective treatment
of tropical snakebite victims. These include, but are not limited to, addressing the poor afford-
ability, lack of availability and the often limited cross-species neutralising potency of commer-
cial antivenom [19,50]. Currently, all existing antivenoms are manufactured for specific
geographical regions, typically parts of a continent, or specific countries within a continent,
leading to a highly fragmented drug market [3,50]. Ultimately, the venoms used as immuno-
gens for antivenom production dictate the breadth of snake species efficacy of those products,
and it has been suggested that simply adding additional venoms to the immunogen mixture to
increase paraspecific efficacy could be potentially counter-productive by diluting those anti-
bodies specific to the toxins delivered during the bite by any particular snake [11,19,32]. Devel-
oping ‘generic’ or worldwide-applicable therapies for snakebite are ultimately confounded by
the complexity in snake venom protein composition, with distinct toxins and therefore antige-
nicities found to vary from one species to another, and even within a single snake species as a
consequence of ontogenetic and geographic variation [42,51].
Despite the challenge posed by venom variation, in the current pilot study we explored the
feasibility of generating a globally efficacious conventional antivenom against haemotoxic
envenoming, based on encouraging recent findings [42,52]. To do so, we used venom from a
variety of geographically and taxonomically diverse and/or medically important haemotoxic
snake species as immunogens. To explore the potential trade-off between antivenom dose effi-
cacy and the number of venoms included in the immunising mixture, we generated two differ-
ent EAVs, each consisting of ovine polyclonal antibodies, but using either seven or twelve
different venoms in the immunising mixture. Time course analysis of the immunological
responses of the sheep over the duration of immunisation (42 weeks), determined by ELISA
analysis of serum samples, demonstrated highly comparable responses to the different immu-
nogen mixtures, and high titres of cross-reactive antibodies resulting by the end of the immu-
nising period. Thereafter, IgG was purified from each 42-week sample for use in in depth
immunological and venom neutralisation experiments.
Despite considerable differences in the two different immunogen mixtures, ELISA and
immunoblotting experiments revealed that both EAVs exhibited high levels of cross-reactivity
and detected the vast majority of the variable protein constituents found in each of the 12
snake venoms (Figs 2 and 3A). The most noticeable exceptions to this were (i) disparities in
the general intensity of immunological cross-reactivity and (ii) differences in the recognition
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of lower molecular weight toxins (i.e. <25 kDa) found in the immunoblotting experiments
with the venoms of the non-front fanged snakes D. typus and R. subminiatus. EAV 2 outper-
formed EAV 1 on both counts, despite D. typus venom being included in both immunising
mixtures, and these findings correlated with the binding levels observed in the end point
ELISA experiments. These findings may be the result of the poor immunogenicity of venom
components with low molecular weight [53–55], and/or due to distinctions between these
non-viper venom components resulting in deficiency of these antigens to stimulate sufficient
specific antibodies for experimental detection [56–58]. Contrastingly, the medium to high
molecular weight toxins found across all of the various venoms (e.g. >25 kDa) were readily
detected by both EAVs; including EAV 1 extensively recognising the majority of venom pro-
teins found in the other venoms (i.e. the viperid venoms) not used as venom immunogens.
The other major and, perhaps more surprising, observation from the immunological assays
was the seemingly low levels of antibody binding, coupled with reduced binding avidities, of
both EAVs against C. rhodostoma venom (Fig 3). This was despite this venom being used as an
immunogen to generate both antivenoms, and there being clear immunological cross-reactiv-
ity observed in the immunoblotting experiments (Fig 2). Notwithstanding these immunologi-
cal observations, in vitro neutralisation assays revealed that both EAVs inhibited C.
rhodostoma SVMP and coagulopathic venom activities in a manner highly comparable to the
other venoms tested (Fig 4D and 4F). Indeed, broadly speaking, both antivenoms exhibited
high levels of SVMP-inhibition against each of the venoms tested, and comparable findings
were observed in terms of coagulotoxin inhibition, with the exception that EAV 2 provided lit-
tle neutralisation effect against E. ocellatus venom at the dose tested, while neither antivenom
inhibited C. atrox venom-induced coagulation. The inhibitory effects of both antivenoms
against SVSP toxin activity was far more variable (Fig 4B), suggesting that both the titre and
specificity of the resulting antibodies generated against these toxins may differ considerably
between the two antivenoms, despite them sharing a number of snake venoms as
immunogens.
One of the major challenges with interpreting the results described above in terms of pre-
dicted antivenom efficacy is that no single in vitro experiment accurately recapitulates the
complex interaction of variable toxins on multiple physiological pathways following a snake-
bite. Indeed, some previous studies have demonstrated that high levels of immunological bind-
ing do not necessary result in effective neutralisation of venom toxicity in vivo [24,32]. Thus,
to preliminarily assess the relative preclinical efficacies of the two EAVs described here, we
employed an ethically-refined version of a previous described murine model of envenoming
[49] and, to robustly investigate paraspecific neutralising capabilities, we used a diverse array
of challenge venoms, including two that were not used as venom immunogens for generating
either antivenom. Despite highly comparable immunological and in vitro inhibitory character-
istics, our in vivo studies demonstrated that EAV 1 exhibited increased in vivo preclinical effi-
cacy than EAV 2, despite fewer venoms being used in the immunogen mixture. Overall, at the
single antivenom dose tested (5 mg [100 μl, 50 mg/ml]), EAV 1 completely protected experi-
mental animals from the lethal venom effects of five of the eight diverse snake venoms tested,
including two not used as immunogens (B. arietans and V. ammodytes) (Fig 5). In addition,
EAV 1 provided some protection against lethality by C. rhodostoma and E. carinatus venoms.
The former finding seems likely to reflect the low immunological binding observed against
this venom, despite it being an immunogen, while the latter finding is more promising since
this venom was not a venom immunogen, yet four of five experimental animals were protected
in a paraspecific manner. EAV 1 was, however, completely ineffective at protecting against the
effects of L.muta venom, a venom that was not included in either immunising mixture. These
findings, which were also observed for EAV 2, suggest that L.muta venom contains lethal
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toxins sufficiently distinct from, or in much greater abundances than, those found in the ven-
oms used as immunogens to prevent any degree of paraspecific neutralisation.
Our in vivo findings revealed that EAV 2 failed to provide complete protection against
venom-induced lethality stimulated by any of the six venoms used as immunogens at the ther-
apeutic doses tested (Fig 5). A degree of protection was observed against five of these six ven-
oms (i.e. some experimental animals survived to the end of experiment), suggesting that the
dose efficacy of EAV 2 is lower than that of EAV 1, and that perhaps with increased antivenom
doses full protection might have been conveyed. Crucially, these findings provide experimental
evidence that increasing the number of venoms in an immunogen mixture could perhaps have
detrimental effects on efficacy, likely by diluting the proportional amount of venom neutralis-
ing antibodies specific to any particular venom via the addition of numerous immunogens (i.e.
those venom toxins unique to the additional venoms used for immunisation). However, it
should be stressed that our in vitro immunological experiments did not predict reductions in
antibody binding to the various crude venoms, and thus more detailed follow up experiments
involving purified toxins or chromatographically separated toxin fractions (i.e. antivenomic-
type approaches [58,59]) are ultimately required to better understand the basis for these effi-
cacy observations. Nonetheless, we suggest that a core set of venoms representing broad toxin
diversity may be sufficient for the generation of antibodies that cross-react with and neutralise
venoms in a paraspecific manner. Experimentally identifying the optimal venom mixture for
immunisation remains challenging though, particularly since using too few venoms seems
likely to result in reduced paraspecific efficacy, whereas too many may cause reductions in
dose efficacy, as observed here.
Despite these findings, there are a number of limitations with the described work. For
example, due to financial constraints, only a single animal was immunised to generate each
EAV, and thus differences between the efficacy of the two antivenoms could be partially due to
the different immune responses of these animals during immunisation. However, the highly
comparable serological responses observed during the immunisation time course (Fig 1), and
the comparable immunological cross-reactivity observed in ELISA and western blotting exper-
iments (Figs 2 and 3), suggest that this is unlikely to be a major confounder of this study,
though future iterations of attempts to generate pathology-focused experimental antivenoms
should, where feasible, increase the number of immunisation animals to offset this risk.
Another limitation relates to the restricted preclinical efficacy testing performed, which was a
result of both ethical and financial constraints imposed on the study. Unlike the described in
vitro neutralisation experiments, murine in vivo neutralisation experiments only utilised a sub-
set of the venoms used as immunogens, and we only tested the generated EAVs at a single, rel-
atively high, experimental therapeutic dose (5 mg [100 μl, 50 mg/ml]). Furthermore, animal
monitoring of acute envenoming was only undertaken for 6 hours due to ethical consider-
ations. Additional preclinical testing, involving those venoms omitted from this pilot work,
and using varying antivenom doses to generate median effective dose data [48] for each
venom, would provide a more complete picture of the efficacy and limitations of each EAV.
However, due to evidence of incomplete neutralisation observed in these pilot studies, and the
apparent need to further optimise the immunisation process to increase the paraspecific effi-
cacy of these pathology-specific antivenoms, such additional experiments in more robust pre-
clinical efficacy models [60] cannot be justified at this time.
Despite these limitations, this pilot study provides at least some evidence that generating
anti-haemotoxicity antivenoms with global efficacy may be a viable future strategy for tackling
snakebite envenoming, analogous with recent findings exploring the potential of pan-conti-
nentally efficacious anti-neurotoxicity antivenoms [41,42]. Careful selection of the specific
venoms and/or venom toxins used as immunogens is of fundamental importance for
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stimulating adequate breadth of neutralisation against diverse snake species without
compromising antivenom potency. Should further optimisation work address these current
shortcomings, pathology-specific antivenoms may offer antivenom manufacturers with
increased economies of scale to produce more sustainable conventional polyspecific anti-
venom products in the short to medium term to address the current therapeutic vacuum relat-
ing to tropical snakebite.
Supporting information
S1 Fig. End point titration ELISA analyses of immunological binding between the two
experimental antivenoms (EAVs) and each of the individual venoms used as immunogens.
The EAVs (EAV 1 and EAV 2), commercial SAIMR polyvalent antivenom (positive control)
and normal sheep IgG and normal horse IgG (negative controls) were serially diluted fivefold
and tested by ELISA against each of the haemotoxic venoms used as immunogens. Venoms
from B. asper, B. jararaca, E. ocellatus, C. rhodostoma, D. typus, D. acutus and D. russelii were
used as immunogens for EAV 1, while all of the venoms shown were used as immunogens for
EAV 2. Error bars represent standard deviation (SD) of duplicate measurements.
(TIF)
S2 Fig. In vitro immunological and neutralisation results for EAVs against each of the
venom immunogen mixtures. A) End-point titration ELISA analysis of immunological bind-
ing between the EAVs and the two venom immunogen mixtures. All antibodies were serially
diluted fivefold with a standardised starting concentration of 50 mg/ml. B) Chaotropic ELISA
showing the relative avidity of the EAVs to the two venom immunogen mixtures in the pres-
ence of increasing molarities of the chaotropic agent ammonium thiocyanate (NH4SCN). The
antibodies were used at a standardised concentration of 70 mg/ml. For both panels A and B,
data points represent the mean of duplicate readings and error bars represent standard devia-
tions. C) Quantification of the neutralisation of snake venom serine protease (SVSP) activity
measured via chromogenic assay. Data points represent the rate of substrate cleavage mea-
sured kinetically. D) Quantification of the neutralisation of snake venom metalloproteinase
(SVMP) activity measured via fluorescent assay. Data points represent area under the curve
(AUC) of kinetic measurements. E) Quantification of the neutralisation of coagulopathic
venom toxins via absorbance-based kinetic plasma clotting assay. The dashed line represents
‘normal clotting’ (i.e. negative control), with readings above the line promoting clotting (i.e.
procoagulant), and those below inhibiting clotting (i.e. anticoagulant). The data represents
percentage areas under the curve of the venom-only control area under the curve. For (C), (D)
and (E) the data points represent the mean of triplicate readings and error bars represent
SEM. Throughout, the antivenoms used consisted of the two EAVs (EAV 1 and EAV 2), the
SAIMR polyvalent antivenom control (positive control), and for the immunological assays,
normal sheep and horse IgG were used as negative controls. PBS was used as the negative con-
trol in the functional assays, and Bitis arietans and Echis ocellatus venom were used as the posi-
tive controls in the serine protease and metalloproteinase assays, respectively.
(TIF)
S3 Fig. The relative avidity of the EAVs to the venoms used as immunogens measured by
immunological binding in the presence of increasing molarities of the chaotropic agent
ammonium thiocyanate (NH4SCN). EAVs (EAV 1 and EAV 2), commercial SAIMR polyva-
lent antivenom (positive control) and normal sheep IgG and normal horse IgG (negative con-
trols) (all at 1:10,000 dilutions) were tested in the presence of increasing concentrations of
ammonium thiocyanate (0-8M). Venoms from B. asper, B. jararaca, E. ocellatus, C.
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rhodostoma, D. typus, D. acutus and D. russelii were used as immunogens for EAV 1, while all
of the venoms shown were used as immunogens for EAV 2. Error bars represent SD of dupli-
cate measurements.
(TIF)
S4 Fig. The serine protease activity of the individual venom immunogens and their inhibi-
tion by the EAVs as measured by kinetic chromogenic assay. The SVSP venom activity
(1 μg) of each individual venom immunogen is displayed as the rate of substrate conversion
(kinetic readings at 405 nm over 30 mins). The antivenoms used consisted of the two EAVs
(EAV 1 and EAV 2) and the commercial SAIMR polyvalent antivenom as an antivenom com-
parator, and PBS was used as the negative control. The positive control used across all experi-
ments was Bitis arietans venom. Data points represent means of triplicate calculated rates, and
error bars represent standard error of the mean (SEM).
(TIF)
S5 Fig. The metalloproteinase activity of the individual venom immunogens and their
inhibition by the EAVs as measured by kinetic fluorescent assay. The SVMP venom activity
(1 μg) of each individual venom immunogen is displayed as area under the kinetic curve
(AUC) of fluorescence (320 nm excitation and 405 nm emission over 40 mins). The antiven-
oms used consisted of the two EAVs (EAV 1 and EAV 2) and the SAIMR polyvalent anti-
venom as an antivenom comparator, and PBS was used as the negative control. The positive
control used across all experiments was Echis ocellatus venom. The data displayed represents
the mean AUC of triplicate measurements and error bars represent standard error of the mean
(SEM).
(TIF)
S6 Fig. The coagulopathic activity of the individual venom immunogens and their inhibi-
tion by the EAVs as measured by plasma coagulation assay. The data displayed shows the
percentage of plasma clotting (normalised to venom only readings) of the means of triplicate
area under the clotting curve measurements (absorbance plotted over time), with error bars
represent the standard error of the mean (SEM). The dashed line represents normal clotting
(i.e. negative control [PBS] readings). The antivenoms used consisted of the two EAVs (EAV 1
and EAV 2) and the SAIMR polyvalent antivenom as an antivenom comparator.
(TIF)
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